Aquestive Therapeutics Investors Eligible for Securities Fraud Lawsuit

Rosen Law Firm announces class action lawsuit on behalf of Aquestive Therapeutics shareholders

Mar. 12, 2026 at 7:05pm

Got story updates? Submit your updates here. ›

The Rosen Law Firm, a global investor rights law firm, has announced a class action lawsuit on behalf of purchasers of Aquestive Therapeutics, Inc. (NASDAQ: AQST) securities between June 16, 2025 and January 8, 2026. The lawsuit alleges that Aquestive made false and/or misleading statements and/or failed to disclose the true state of the company's New Drug Application for its product Anaphylm, including issues with packaging, use, administration, and labeling.

Why it matters

This lawsuit represents an opportunity for Aquestive Therapeutics investors to seek compensation for potential losses related to the alleged securities fraud. The case highlights the importance of transparency and accurate disclosures by publicly traded companies, as investors rely on this information to make informed decisions.

The details

According to the lawsuit, Aquestive Therapeutics concealed or minimized the significance of human factors involved in the use and deployment of its sublingual film product, such as packaging, use, administration, and labeling. When these issues came to light, the lawsuit claims that investors suffered damages as a result.

  • The class period for the lawsuit is from June 16, 2025 to January 8, 2026, both dates inclusive.
  • Investors have until May 4, 2026 to move the court to serve as lead plaintiff in the class action lawsuit.

The players

Aquestive Therapeutics, Inc.

A pharmaceutical company that develops and commercializes various products to address unmet patient needs.

The Rosen Law Firm, P.A.

A global investor rights law firm that represents investors throughout the world, concentrating its practice in securities class actions and shareholder derivative litigation.

Got photos? Submit your photos here. ›

What they’re saying

“We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel.”

— Laurence Rosen, Founding Partner, The Rosen Law Firm (The Rosen Law Firm)

What’s next

Investors have until May 4, 2026 to move the court to serve as lead plaintiff in the class action lawsuit.

The takeaway

This case highlights the importance of transparency and accurate disclosures by publicly traded companies, as investors rely on this information to make informed decisions. The Rosen Law Firm's class action lawsuit provides an opportunity for Aquestive Therapeutics investors to seek compensation for potential losses related to the alleged securities fraud.